Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double-blind study

Area of Science:

• Pediatric Neurology
• Clinical Pharmacology
• Epilepsy Management

Background:

• Generalized tonic-clonic convulsions (GTC) are a common form of epilepsy in children.
• Effective anticonvulsant therapy is crucial for managing GTC and improving quality of life.
• Choosing between phenobarbitone (PB), phenytoin (PHT), and sodium valproate (SVP) involves balancing efficacy and side effect profiles.

Purpose of the Study:

• To compare the efficacy of phenobarbitone, phenytoin, and sodium valproate in controlling GTC in children.
• To evaluate and compare the side effect profiles of these three anticonvulsant medications.
• To provide evidence-based recommendations for the first-line treatment of GTC in pediatric populations.

Main Methods:

• A randomized, double-blind clinical trial was conducted with 151 children aged 4-12 years diagnosed with GTC.
• Participants received either phenobarbitone, phenytoin, or sodium valproate, alongside placebo tablets.
• Outcomes measured included seizure recurrence and the incidence and type of adverse events over a two-year follow-up period.

Main Results:

• No significant difference in seizure recurrence rates was observed among the three treatment groups.
• Sodium valproate exhibited the lowest incidence of side effects (19%), followed by phenobarbitone (32%) and phenytoin (40%).
• Hyperactivity was the most common side effect associated with phenobarbitone (22%), while phenytoin-related side effects often resolved with dosage adjustments.

Conclusions:

• Phenobarbitone, phenytoin, and sodium valproate are equally effective in managing pediatric GTC.
• Sodium valproate is associated with the fewest side effects, making it a favorable option for school-aged children.
• Phenobarbitone, being cost-effective, may be considered for pre-school children, while sodium valproate is recommended for school-aged children due to its better tolerability.